Prostate Cancer Peripheral Blood NK Cells Show Enhanced CD9, CD49a, CXCR4, CXCL8, MMP-9 Production and Secrete Monocyte-Recruiting and Polarizing Factors.
angiogenesis
immune cell polarization
inflammation
macrophages
monocytes
myeloid cells
natural killer cell
prostate cancer
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
22
07
2020
accepted:
08
12
2020
entrez:
11
2
2021
pubmed:
12
2
2021
medline:
16
6
2021
Statut:
epublish
Résumé
Natural killer (NK) cells, effector lymphocytes of the innate immunity, have been shown to be altered in several cancers, both at tissue and peripheral levels. We have shown that in Non-Small Cell Lung Cancer (NSCLC) and colon cancer, tumour associated circulating NK (TA-NK) and tumour infiltrating NK (TI-NK) exhibit pro-angiogenic phenotype/functions. However, there is still a lack of knowledge concerning the phenotype of peripheral blood (PB) NK (pNK) cells in prostate cancer (PCa). Here, we phenotypically and functionally characterized pNK from PCa patients (PCa TA-NKs) and investigated their interactions with endothelial cells and monocytes/macrophages. NK cell subset distribution in PB of PCa patients was investigated, by multicolor flow cytometry, for surface antigens expression. Protein arrays were performed to characterize the secretome on FACS-sorted pNK cells. Conditioned media (CM) from FACS-sorted PCa pTA-NKs were used to determine their ability to induce pro-inflammatory/pro-angiogenic phenotype/functions in endothelial cells, monocytes, and macrophages. CM from three different PCa (PC-3, DU-145, LNCaP) cell lines, were used to assess their effects on human NK cell polarization
Identifiants
pubmed: 33569050
doi: 10.3389/fimmu.2020.586126
pmc: PMC7868409
doi:
Substances chimiques
Biomarkers, Tumor
0
Cytokines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
586126Informations de copyright
Copyright © 2021 Gallazzi, Baci, Mortara, Bosi, Buono, Naselli, Guarneri, Dehò, Capogrosso, Albini, Noonan and Bruno.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Prostate Cancer Prostatic Dis. 2013 Mar;16(1):1-6
pubmed: 22751145
Oncogene. 2017 Nov 2;36(44):6143-6153
pubmed: 28692048
Cancer Cell. 2017 Aug 14;32(2):135-154
pubmed: 28810142
Int Immunopharmacol. 2015 Dec;29(2):635-641
pubmed: 26428847
Immunol Rev. 2008 Apr;222:145-54
pubmed: 18363999
Cancer Res. 2016 Apr 15;76(8):2153-65
pubmed: 27197252
Nat Rev Cancer. 2007 Apr;7(4):256-69
pubmed: 17384581
Eur Urol Focus. 2016 Oct;2(4):374-382
pubmed: 28723469
Front Immunol. 2013 Jan 04;3:403
pubmed: 23316194
Front Immunol. 2020 Jul 02;11:1242
pubmed: 32714321
Int J Mol Sci. 2018 Dec 27;20(1):
pubmed: 30591689
Front Cell Infect Microbiol. 2020 Feb 13;10:49
pubmed: 32117816
Front Immunol. 2017 Apr 28;8:510
pubmed: 28503177
Nat Rev Immunol. 2013 Feb;13(2):145-9
pubmed: 23348417
Cell. 2018 Aug 23;174(5):1054-1066
pubmed: 30142344
Cancer Res. 2007 Jul 15;67(14):6854-62
pubmed: 17638896
Immunol Invest. 2015;44(6):578-89
pubmed: 26214042
Res Rep Urol. 2014 May 09;6:27-34
pubmed: 24892030
Nat Rev Cancer. 2017 Aug;17(8):457-474
pubmed: 28706266
Methods Enzymol. 2020;635:1-20
pubmed: 32122539
Front Oncol. 2019 Sep 11;9:884
pubmed: 31572678
Neoplasia. 2013 Feb;15(2):133-42
pubmed: 23441128
Front Oncol. 2020 Aug 14;10:1330
pubmed: 32923385
Front Oncol. 2020 Mar 11;10:324
pubmed: 32219066
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Clin Cancer Res. 2015 Mar 15;21(6):1248-57
pubmed: 25589616
Cancer Discov. 2016 Apr;6(4):414-29
pubmed: 26873347
Cancers (Basel). 2019 Apr 01;11(4):
pubmed: 30939820
Oncotarget. 2015 Jun 10;6(16):14360-73
pubmed: 25961317
Front Immunol. 2019 Apr 18;10:771
pubmed: 31057536
Blood. 2008 Aug 1;112(3):461-9
pubmed: 18650461
J Natl Cancer Inst. 1998 Nov 4;90(21):1648-53
pubmed: 9811314
Nat Rev Clin Oncol. 2014 Jun;11(6):365-76
pubmed: 24840076
Cancers (Basel). 2014 Jun 27;6(3):1298-327
pubmed: 24978435
Clin Cancer Res. 2011 Jun 15;17(12):3892-902
pubmed: 21680545
Front Immunol. 2018 Apr 05;9:527
pubmed: 29675018
J Exp Clin Cancer Res. 2019 Jul 19;38(1):321
pubmed: 31324197
Future Sci OA. 2017 Nov 15;4(2):FSO266
pubmed: 29379640
Oncotarget. 2016 Nov 8;7(45):72961-72977
pubmed: 27662664
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
J Leukoc Biol. 2019 Aug;106(2):309-322
pubmed: 30776148
Int J Oncol. 2008 Apr;32(4):757-65
pubmed: 18360703
Cell. 2017 May 4;169(4):750-765.e17
pubmed: 28475900
Cancer Gene Ther. 2010 Sep;17(9):599-613
pubmed: 20448670
Clin Cancer Res. 2017 Nov 15;23(22):6764-6770
pubmed: 28663235
Immunol Lett. 2018 Nov;203:102-111
pubmed: 30218741
J Reprod Immunol. 2011 Mar;88(2):86-92
pubmed: 21227511
Cancer Res. 2020 Apr 15;80(8):1615-1623
pubmed: 32066566
Front Immunol. 2019 Jan 25;9:3169
pubmed: 30761160
Nat Rev Immunol. 2018 Nov;18(11):671-688
pubmed: 30209347
Nat Rev Urol. 2020 Jun;17(6):321-338
pubmed: 32358562
Immunity. 2014 Jul 17;41(1):14-20
pubmed: 25035950
Immunity. 2019 Apr 16;50(4):924-940
pubmed: 30995507
Front Immunol. 2020 Jan 21;10:3038
pubmed: 32038612
Mol Oncol. 2018 Mar;12(3):269-286
pubmed: 28865178
Front Immunol. 2018 Aug 13;9:1808
pubmed: 30150983
Front Oncol. 2015 Jul 08;5:128
pubmed: 26217583
J Immunol Res. 2018 Mar 29;2018:2438598
pubmed: 29713652
J Immunol Methods. 2009 Aug 31;348(1-2):9-17
pubmed: 19552894
Hepatology. 2013 Mar;57(3):1107-16
pubmed: 23225218
Trends Immunol. 2010 Jun;31(6):220-7
pubmed: 20538542
PLoS One. 2008 May 14;3(5):e2150
pubmed: 18478075
Oncogene. 2008 Nov 27;27(56):7118-30
pubmed: 18724388
PLoS One. 2012;7(5):e36928
pubmed: 22629344
Cancer. 2008 Feb 15;112(4):863-75
pubmed: 18203207
Science. 2018 Mar 23;359(6382):1344-1345
pubmed: 29567702
J Clin Invest. 2012 Mar;122(3):787-95
pubmed: 22378047
Elife. 2020 Jul 28;9:
pubmed: 32717179
Prostate. 2019 Mar;79(4):363-369
pubmed: 30500076
Oncotarget. 2015 May 30;6(15):13835-43
pubmed: 26079948
Exp Cell Res. 2018 Mar 1;364(1):113-123
pubmed: 29408565
Front Oncol. 2014 Jul 02;4:131
pubmed: 25072019
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Med. 2006 Sep;12(9):1065-74
pubmed: 16892062
Cancer Immunol Res. 2014 May;2(5):410-22
pubmed: 24795354
FASEB J. 2018 Oct;32(10):5365-5377
pubmed: 29763380
Cancers (Basel). 2020 Oct 15;12(10):
pubmed: 33076397
J Cell Sci. 2012 Dec 1;125(Pt 23):5591-6
pubmed: 23420197
Cancer Immunol Res. 2018 Dec;6(12):1548-1560
pubmed: 30282672
Eur J Immunol. 2014 Jun;44(6):1814-22
pubmed: 24510590
Mol Cancer Res. 2020 Jan;18(1):153-165
pubmed: 31604846